Loading…
The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin
The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age...
Saved in:
Published in: | Biomolecules (Basel, Switzerland) Switzerland), 2020-08, Vol.10 (8), p.1192 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3 |
---|---|
cites | cdi_FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3 |
container_end_page | |
container_issue | 8 |
container_start_page | 1192 |
container_title | Biomolecules (Basel, Switzerland) |
container_volume | 10 |
creator | Skaanning, Line K Santoro, Angelo Skamris, Thomas Martinsen, Jacob Hertz D'Ursi, Anna Maria Bucciarelli, Saskia Vestergaard, Bente Bugge, Katrine Langkilde, Annette Eva Kragelund, Birthe B |
description | The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN
/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN
co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN
, through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation. |
doi_str_mv | 10.3390/biom10081192 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_92facbcc1ebc42919c683d2bbed16a12</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_92facbcc1ebc42919c683d2bbed16a12</doaj_id><sourcerecordid>2436394340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3</originalsourceid><addsrcrecordid>eNpdkU1rFDEYxwdRbKm9eZaAFw-O5m0yk4tgF2sLpR7cgreQl2d2s8wkazKj9GP1i_QzmXZr3RoCCckvP548_6p6TfAHxiT-aHwcCcYdIZI-qw4pJV1NW_bj-d7-oDrOeYPL6Mqk7GV1wGhHOWvFYXW1XAO6jKE-9Sb5YdCTDyt0WS8hjT7oAcUe3d7U36_DbAfwAZ344DLSwaFF_PcIMvrtpzU6g61OPryqXvR6yHD8sB5VV6dflouz-uLb1_PF54va8rabaiJkS4XgWGvgrSW4wb0ErAkzREvrnDWWAHDnQPZMYNNgKYSlVDYNY8axo-p853VRb9Q2-VGnaxW1V_cHMa2UTpMvlStJe110xWcsp5JIKzrmqDHgiNCEFtennWs7mxGchTAlPTyRPr0Jfq1W8ZdquShCXATvHgQp_pwhT2r02UJpT4A4Z1U6LpjkjN-hb_9DN3FOpd33VNO1JZuuUO93lE0x5wT9YzEEq7v41X78BX-z_4FH-G_Y7A_kcKvJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435873768</pqid></control><display><type>article</type><title>The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Skaanning, Line K ; Santoro, Angelo ; Skamris, Thomas ; Martinsen, Jacob Hertz ; D'Ursi, Anna Maria ; Bucciarelli, Saskia ; Vestergaard, Bente ; Bugge, Katrine ; Langkilde, Annette Eva ; Kragelund, Birthe B</creator><creatorcontrib>Skaanning, Line K ; Santoro, Angelo ; Skamris, Thomas ; Martinsen, Jacob Hertz ; D'Ursi, Anna Maria ; Bucciarelli, Saskia ; Vestergaard, Bente ; Bugge, Katrine ; Langkilde, Annette Eva ; Kragelund, Birthe B</creatorcontrib><description>The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN
/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN
co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN
, through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation.</description><identifier>ISSN: 2218-273X</identifier><identifier>EISSN: 2218-273X</identifier><identifier>DOI: 10.3390/biom10081192</identifier><identifier>PMID: 32824376</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Aggregates ; alpha-Synuclein - chemistry ; alpha-Synuclein - metabolism ; Anticoagulants ; binding ; Binding Sites ; Circular Dichroism ; Dialysate ; Fibrillation ; Fibrils ; Fluorescence microscopy ; Glycerol ; Glycosaminoglycans ; Heparan sulfate ; Heparan sulfate proteoglycans ; Heparin ; Heparin - metabolism ; Humans ; IDP ; Lewy bodies ; Microscopy, Fluorescence ; Models, Molecular ; Movement disorders ; Neurodegenerative diseases ; NMR ; Nuclear magnetic resonance ; Parkinson's disease ; Physiology ; Protein Binding ; Protein Domains ; Protein Structure, Secondary ; Proteins ; Proteoglycans ; Spectrum analysis ; Sulfates ; Synuclein ; α-synuclein</subject><ispartof>Biomolecules (Basel, Switzerland), 2020-08, Vol.10 (8), p.1192</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3</citedby><cites>FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3</cites><orcidid>0000-0001-9874-1138 ; 0000-0002-7454-1761 ; 0000-0003-2467-4205 ; 0000-0001-7612-223X ; 0000-0002-7679-6143 ; 0000-0002-6286-6243 ; 0000-0002-9690-907X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2435873768/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2435873768?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32824376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Skaanning, Line K</creatorcontrib><creatorcontrib>Santoro, Angelo</creatorcontrib><creatorcontrib>Skamris, Thomas</creatorcontrib><creatorcontrib>Martinsen, Jacob Hertz</creatorcontrib><creatorcontrib>D'Ursi, Anna Maria</creatorcontrib><creatorcontrib>Bucciarelli, Saskia</creatorcontrib><creatorcontrib>Vestergaard, Bente</creatorcontrib><creatorcontrib>Bugge, Katrine</creatorcontrib><creatorcontrib>Langkilde, Annette Eva</creatorcontrib><creatorcontrib>Kragelund, Birthe B</creatorcontrib><title>The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin</title><title>Biomolecules (Basel, Switzerland)</title><addtitle>Biomolecules</addtitle><description>The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN
/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN
co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN
, through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation.</description><subject>Age</subject><subject>Aggregates</subject><subject>alpha-Synuclein - chemistry</subject><subject>alpha-Synuclein - metabolism</subject><subject>Anticoagulants</subject><subject>binding</subject><subject>Binding Sites</subject><subject>Circular Dichroism</subject><subject>Dialysate</subject><subject>Fibrillation</subject><subject>Fibrils</subject><subject>Fluorescence microscopy</subject><subject>Glycerol</subject><subject>Glycosaminoglycans</subject><subject>Heparan sulfate</subject><subject>Heparan sulfate proteoglycans</subject><subject>Heparin</subject><subject>Heparin - metabolism</subject><subject>Humans</subject><subject>IDP</subject><subject>Lewy bodies</subject><subject>Microscopy, Fluorescence</subject><subject>Models, Molecular</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Parkinson's disease</subject><subject>Physiology</subject><subject>Protein Binding</subject><subject>Protein Domains</subject><subject>Protein Structure, Secondary</subject><subject>Proteins</subject><subject>Proteoglycans</subject><subject>Spectrum analysis</subject><subject>Sulfates</subject><subject>Synuclein</subject><subject>α-synuclein</subject><issn>2218-273X</issn><issn>2218-273X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU1rFDEYxwdRbKm9eZaAFw-O5m0yk4tgF2sLpR7cgreQl2d2s8wkazKj9GP1i_QzmXZr3RoCCckvP548_6p6TfAHxiT-aHwcCcYdIZI-qw4pJV1NW_bj-d7-oDrOeYPL6Mqk7GV1wGhHOWvFYXW1XAO6jKE-9Sb5YdCTDyt0WS8hjT7oAcUe3d7U36_DbAfwAZ344DLSwaFF_PcIMvrtpzU6g61OPryqXvR6yHD8sB5VV6dflouz-uLb1_PF54va8rabaiJkS4XgWGvgrSW4wb0ErAkzREvrnDWWAHDnQPZMYNNgKYSlVDYNY8axo-p853VRb9Q2-VGnaxW1V_cHMa2UTpMvlStJe110xWcsp5JIKzrmqDHgiNCEFtennWs7mxGchTAlPTyRPr0Jfq1W8ZdquShCXATvHgQp_pwhT2r02UJpT4A4Z1U6LpjkjN-hb_9DN3FOpd33VNO1JZuuUO93lE0x5wT9YzEEq7v41X78BX-z_4FH-G_Y7A_kcKvJ</recordid><startdate>20200816</startdate><enddate>20200816</enddate><creator>Skaanning, Line K</creator><creator>Santoro, Angelo</creator><creator>Skamris, Thomas</creator><creator>Martinsen, Jacob Hertz</creator><creator>D'Ursi, Anna Maria</creator><creator>Bucciarelli, Saskia</creator><creator>Vestergaard, Bente</creator><creator>Bugge, Katrine</creator><creator>Langkilde, Annette Eva</creator><creator>Kragelund, Birthe B</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9874-1138</orcidid><orcidid>https://orcid.org/0000-0002-7454-1761</orcidid><orcidid>https://orcid.org/0000-0003-2467-4205</orcidid><orcidid>https://orcid.org/0000-0001-7612-223X</orcidid><orcidid>https://orcid.org/0000-0002-7679-6143</orcidid><orcidid>https://orcid.org/0000-0002-6286-6243</orcidid><orcidid>https://orcid.org/0000-0002-9690-907X</orcidid></search><sort><creationdate>20200816</creationdate><title>The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin</title><author>Skaanning, Line K ; Santoro, Angelo ; Skamris, Thomas ; Martinsen, Jacob Hertz ; D'Ursi, Anna Maria ; Bucciarelli, Saskia ; Vestergaard, Bente ; Bugge, Katrine ; Langkilde, Annette Eva ; Kragelund, Birthe B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Aggregates</topic><topic>alpha-Synuclein - chemistry</topic><topic>alpha-Synuclein - metabolism</topic><topic>Anticoagulants</topic><topic>binding</topic><topic>Binding Sites</topic><topic>Circular Dichroism</topic><topic>Dialysate</topic><topic>Fibrillation</topic><topic>Fibrils</topic><topic>Fluorescence microscopy</topic><topic>Glycerol</topic><topic>Glycosaminoglycans</topic><topic>Heparan sulfate</topic><topic>Heparan sulfate proteoglycans</topic><topic>Heparin</topic><topic>Heparin - metabolism</topic><topic>Humans</topic><topic>IDP</topic><topic>Lewy bodies</topic><topic>Microscopy, Fluorescence</topic><topic>Models, Molecular</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Parkinson's disease</topic><topic>Physiology</topic><topic>Protein Binding</topic><topic>Protein Domains</topic><topic>Protein Structure, Secondary</topic><topic>Proteins</topic><topic>Proteoglycans</topic><topic>Spectrum analysis</topic><topic>Sulfates</topic><topic>Synuclein</topic><topic>α-synuclein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Skaanning, Line K</creatorcontrib><creatorcontrib>Santoro, Angelo</creatorcontrib><creatorcontrib>Skamris, Thomas</creatorcontrib><creatorcontrib>Martinsen, Jacob Hertz</creatorcontrib><creatorcontrib>D'Ursi, Anna Maria</creatorcontrib><creatorcontrib>Bucciarelli, Saskia</creatorcontrib><creatorcontrib>Vestergaard, Bente</creatorcontrib><creatorcontrib>Bugge, Katrine</creatorcontrib><creatorcontrib>Langkilde, Annette Eva</creatorcontrib><creatorcontrib>Kragelund, Birthe B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Biomolecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Skaanning, Line K</au><au>Santoro, Angelo</au><au>Skamris, Thomas</au><au>Martinsen, Jacob Hertz</au><au>D'Ursi, Anna Maria</au><au>Bucciarelli, Saskia</au><au>Vestergaard, Bente</au><au>Bugge, Katrine</au><au>Langkilde, Annette Eva</au><au>Kragelund, Birthe B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin</atitle><jtitle>Biomolecules (Basel, Switzerland)</jtitle><addtitle>Biomolecules</addtitle><date>2020-08-16</date><risdate>2020</risdate><volume>10</volume><issue>8</issue><spage>1192</spage><pages>1192-</pages><issn>2218-273X</issn><eissn>2218-273X</eissn><abstract>The intrinsically disordered protein α-synuclein (aSN) is, in its fibrillated state, the main component of Lewy bodies-hallmarks of Parkinson's disease. Additional Lewy body components include glycosaminoglycans, including heparan sulfate proteoglycans. In humans, heparan sulfate has, in an age-dependent manner, shown increased levels of sulfation. Heparin, a highly sulfated glycosaminoglycan, is a relevant mimic for mature heparan sulfate and has been shown to influence aSN fibrillation. Here, we decompose the underlying properties of the interaction between heparin and aSN and the effect of heparin on fibrillation. Via the isolation of the first 61 residues of aSN, which lacked intrinsic fibrillation propensity, fibrillation could be induced by heparin, and access to the initial steps in fibrillation was possible. Here, structural changes with shifts from disorder via type I β-turns to β-sheets were revealed, correlating with an increase in the aSN
/heparin molar ratio. Fluorescence microscopy revealed that heparin and aSN
co-exist in the final fibrils. We conclude that heparin can induce the fibrillation of aSN
, through binding to the N-terminal with an affinity that is higher in the truncated form of aSN. It does so by specifically modulating the structure of aSN via the formation of type I β-turn structures likely critical for triggering aSN fibrillation.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32824376</pmid><doi>10.3390/biom10081192</doi><orcidid>https://orcid.org/0000-0001-9874-1138</orcidid><orcidid>https://orcid.org/0000-0002-7454-1761</orcidid><orcidid>https://orcid.org/0000-0003-2467-4205</orcidid><orcidid>https://orcid.org/0000-0001-7612-223X</orcidid><orcidid>https://orcid.org/0000-0002-7679-6143</orcidid><orcidid>https://orcid.org/0000-0002-6286-6243</orcidid><orcidid>https://orcid.org/0000-0002-9690-907X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2218-273X |
ispartof | Biomolecules (Basel, Switzerland), 2020-08, Vol.10 (8), p.1192 |
issn | 2218-273X 2218-273X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_92facbcc1ebc42919c683d2bbed16a12 |
source | Publicly Available Content Database; PubMed Central |
subjects | Age Aggregates alpha-Synuclein - chemistry alpha-Synuclein - metabolism Anticoagulants binding Binding Sites Circular Dichroism Dialysate Fibrillation Fibrils Fluorescence microscopy Glycerol Glycosaminoglycans Heparan sulfate Heparan sulfate proteoglycans Heparin Heparin - metabolism Humans IDP Lewy bodies Microscopy, Fluorescence Models, Molecular Movement disorders Neurodegenerative diseases NMR Nuclear magnetic resonance Parkinson's disease Physiology Protein Binding Protein Domains Protein Structure, Secondary Proteins Proteoglycans Spectrum analysis Sulfates Synuclein α-synuclein |
title | The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A17%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Non-Fibrillating%20N-Terminal%20of%20%CE%B1-Synuclein%20Binds%20and%20Co-Fibrillates%20with%20Heparin&rft.jtitle=Biomolecules%20(Basel,%20Switzerland)&rft.au=Skaanning,%20Line%20K&rft.date=2020-08-16&rft.volume=10&rft.issue=8&rft.spage=1192&rft.pages=1192-&rft.issn=2218-273X&rft.eissn=2218-273X&rft_id=info:doi/10.3390/biom10081192&rft_dat=%3Cproquest_doaj_%3E2436394340%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-169726640aae47c1050f9e0a13b1a9cddcbc1ee4dde9f360b50966c2295533bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2435873768&rft_id=info:pmid/32824376&rfr_iscdi=true |